Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Hueber W., Sands BE., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins PDR., Wehkamp J., Feagan BG., Yao MD., Karczewski M., Karczewski J., Pezous N., Bek S., Bruin G., Mellgard B., Berger C., Londei M., Bertolino AP., Tougas G., Travis SPL.

DOI

10.1136/gutjnl-2011-301668

Type

Journal article

Journal

Gut

Publisher

BMJ

Publication Date

12/2012

Volume

61

Pages

1693 - 1700

Permalink Original publication